The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 28th 2025
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.
Combining Surgery and Biologic Therapy Improves Outcomes in Patients With CRSwNP
August 26th 2023Combination endoscopic sinus surgery (ESS) and biological therapy significantly decreased polyp burden in refractory chronic rhinosinusitis with nasal polyposis (CRSwNP) compared with biologic therapy alone
Read More
Second-Line Axi-Cel Produces Complete Metabolic Responses in Transplant-Ineligible LBCL
August 24th 2023Second-line treatment with axicabtagene ciloleucel (axi-cel) led to an investigator-assessed, 3-month complete metabolic response rate of 71.0% in patients with large B-cell lymphoma (LBCL) who were ineligible for autologous stem cell transplant.
Read More
Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL
August 23rd 2023Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
Watch
Review: Venetoclax Plus HMAs Offer “Moderate” Benefit in AML/MDS After Relapse Post Transplant
August 22nd 2023There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation.
Read More
Dr Kevin Davies Discusses Challenges of Streamlining CRISPR Technology Delivery
August 19th 2023Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, and author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, discusses the difficulties inherent in making CRISPR gene editing technology an equitable treatment.
Watch
Dr Gustavo Fonseca on Key Takeaways From an FCS Analysis on Clinical Trial Enrollment
August 19th 2023Gustavo Fonseca, MD, FACP, physician director of clinical research, Florida Cancer Specialists & Research Institute (FCS), discusses the results from a late phase complexity analysis on barriers to clinical trials regarding biopsy requirements.
Watch
Time to Treatment Initiation Affected by Demographics, Socioeconomics in CRC, NSCLC
August 18th 2023Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of time to treatment initiation.
Read More